Fokusin modified release capsules 0.4mg №30

Modified release capsules

Composition

1 caps contains Tamsulosin hydrochloride 400 mcg, auxiliary substances: methacrylic acid-ethyl acrylate copolymer (1: 1) dispersion 30%, microcrystalline cellulose, dibutylsebactate, polysorbate 80, colloidal silicon dioxide, talc

Packaging

30 pieces

Mechanism of action

Fokusin - α1-adrenoreceptor blocker. Selectively and competitively blocks postsynaptic α1A adrenoreceptors located in the smooth muscles of the prostate gland, bladder neck and prostatic part of the urethra, as well as α1D adrenoreceptors, mainly in the body of the bladder. This leads to a decrease in the tone of the smooth muscles of the prostate gland, the bladder neck and the prostatic part of the urethra and the improvement of the function of the detrusor. Due to this, the symptoms of obstruction and irritation associated with benign prostatic hyperplasia are reduced. As a rule, the therapeutic effect develops 2 weeks after the start of the drug, although in a number of patients a decrease in the severity of symptoms occurs after taking the first dose.

Indications and usage

Treatment of functional disorders in benign prostatic hyperplasia.

Contraindications

Hypersensitivity to the drug.
With care: chronic renal failure (lower creatinine clearance below 10 ml / min), arterial hypotension (including orthostatic), severe hepatic failure.

Dosage and administration

Fokusin is prescribed orally at a dose of 400 μg (1 capsule) per day. Capsules are taken after the first meal, drinking plenty of water. Capsule is not recommended to chew.

Adverse reactions

Rarely - headache, dizziness, asthenia, sleep disturbance (drowsiness or insomnia), retrograde ejaculation, decreased libido, back pain, rhinitis, nausea, vomiting, constipation or diarrhea.
In rare cases - orthostatic hypotension, tachycardia, palpitations, chest pain.
In extremely rare cases - hypersensitivity reactions (skin rash, itching, angioedema).

Special notes

Tamsulosin should be used with caution in patients with a predisposition to orthostatic hypotension. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should be seated or laid.
Before starting to use the drug, it is necessary to verify the diagnosis.
During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Drug interactions

Cimetidine increases plasma concentration, reduces Furosemide (does not have significant clinical significance). Diclofenac and indirect anticoagulants slightly increase the rate of elimination of tamsulosin.
The simultaneous use of tamsulosin with other alpha₁-adrenergic blockers may lead to a pronounced increase in the hypotension-viable effect.

Overdosage

No cases of acute overdose of the drug.
Symptoms:theoretically, the occurrence of acute hypotension.
Treatment:conduct cardiotropic therapy. If symptoms persist, volume-substituting solutions or vasoconstrictor preparations should be injected. To prevent further absorption of tamsulosin, gastric lavage, taking Activated carbon or osmotic laxative are possible.

In the dark place at a temperature of no higher than 25 ° C.